Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this orthokeratology study is to evaluate the safety and effectiveness of the Arise Orthokeratology Lens with non-spherical posterior peripheral curves
The Bausch + Lomb Vision Shaping Treatment VST is based on a reverse geometry orthokeratology design that includes a base curve/treatment curve, a reverse curve, alignment curves and peripheral curves. The base curve is used to only flatten the cornea and is not considered a fitting curve. The parameters of the Arise Orthokeratology Lens are controlled to be within the bounds determined by the spherical posterior curves of other lens designs prescribed for the Bausch + Lomb Vision Shaping Treatment. The term peripheral curves excludes the base curve and includes the zones defined as the reverse curve, alignment curves and peripheral curves. Peripheral curves are designed to help control centration of the lens. When there are elevation differences between the flat and steep meridians on the cornea (e.g., corneal toricity), spherical peripheral curves, including the reverse curve, alignment curves and peripheral curves, may not align completely to the cornea and can result in a lens with sub-optimal centration. Aspheric curves and toric (e.g., dual axis) peripheral curves on reverse geometry lenses for overnight orthokeratology have been available in the US market for more than 10 years for fitting lenses. The intent of the Arise Orthokeratology Lens is to provide a stable and centered lens that helps ensure the treatment zone of the lens is well positioned in relation to the pupil and is shaping the central portion of the cornea for optimal results.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Safety and effectiveness of the Arise Orthokeratology Lens | Experimental | Treatment effect of overnight orthokeratology over a 3-month period |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| orthokeratology lens | Device | Each subject will wear the study lenses in both eyes overnight for approximately 3 months. |
|
| Measure | Description | Time Frame |
|---|---|---|
| The Rate of Serious Adverse Events at the Subject Level | Assessed from dispensing through 3 months | |
| Percentage of Subjects Who Achieve Monocular Uncorrected Distance Visual Acuity (UDVA) of 20/40 or Better in Both Eyes | Using the high contrast distance UDVA collected at the 3-Month Follow-up Visit, subjects with non-missing Snellen VA of 20/40 or less in both eyes will be classified as "20/40 or Better". Subjects with at least one missing value at the 3-Month Follow-up Visit will not be classified and their classification value will be assigned as a missing value. The denominator for percentages will be the number of non-missing values | Assessed at 3 month follow up visit |
| The Rate of Serious Adverse Events at the Eye Level | Assessed from dispensing through 3 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Subject is considered by the Investigator, to not be a suitable candidate for participation or it is not in the best interest of the subject to participate in the study.
Subjects who have worn rigid gas permeable (RGP) contact lenses within the last 30 days or who have worn polymethylmethacrylate (PMMA) lenses within the last three months.
Prior eyelid, strabismus, intraocular, or refractive surgery.
Keratoconus or an irregular cornea.
Subjects with any systemic disease currently affecting ocular health or in the Investigator's opinion may have an effect on ocular health during the course of the study.
Subjects using any systemic or topical medications that will, in the Investigator's opinion, affect ocular physiology or lens performance.
A known allergy to fluorescein, benoxinate, or proparacaine.
A history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, ocular viral or fungal infections or recurrent ocular infections.
Subjects with an active ocular disease or who are using any ocular medication.
Subjects with any Grade 2 or greater finding during the slit lamp examination. Subjects with corneal infiltrates, of ANY GRADE, are NOT eligible. Refer to Appendix B: Methods of Clinical Evaluation.
Subjects with any "Present" finding during the slit lamp examination that, in the Investigator's judgement, interferes with contact lens wear. Refer to Appendix B: Methods of Clinical evaluation.
Subjects with any scar or neovascularization within the central 6mm of the cornea. Subjects with minor peripheral corneal scarring (that does not extend into the central area), that in the Investigator's judgement, does not interfere with contact lens wear, are eligible for this study.
Subjects participating in any drug or device clinical investigation within 2 weeks prior to entry into this study (Screening Visit) and/or planning to do so during the period of study participation.
Subjects who are amblyopic.
Immediate family or close relative is a member of the office staff, including the Investigator(s).
Females of childbearing potential (those who are not surgically sterilized or postmenopausal) if they meet any one of the following:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Levenson Eye Associates | Jacksonville | Florida | 32204 | United States | ||
| Birmingham Vision Care P.C. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Safety and Effectiveness of the Arise Orthokeratology Lens | Treatment effect of overnight orthokeratology over a 3-month period orthokeratology lens: Each subject will wear the study lenses in both eyes overnight for approximately 3 months. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dispensing |
| |||||||||||||
| Study Treatment |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Safety and Effectiveness of the Arise Orthokeratology Lens | Treatment effect of overnight orthokeratology over a 3-month period orthokeratology lens: Each subject will wear the study lenses in both eyes overnight for approximately 3 months. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | The Rate of Serious Adverse Events at the Subject Level | Posted | Count of Participants | Participants | Assessed from dispensing through 3 months |
|
|
AE data collected over all scheduled follow-up visits approximately 3 months after study lens dispensed
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Safety and Effectiveness of the Arise Orthokeratology Lens | Treatment effect of overnight orthokeratology over a 3-month period orthokeratology lens: Each subject will wear the study lenses in both eyes overnight for approximately 3 months. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Corneal abrasion | Injury, poisoning and procedural complications | MeDRA | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Director, Medical Affairs, Vision Care R&D | Bausch & Lomb Incorporated | 585-413-6397 | marjorie.rah@bausch.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Nov 30, 2023 | Jul 17, 2025 | Prot_SAP_000.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009216 | Myopia |
| ID | Term |
|---|---|
| D012030 | Refractive Errors |
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Bloomfield |
| Michigan |
| 48301 |
| United States |
| Cornea and Contact Lens Institute of Minnesota | Edina | Minnesota | 55436 | United States |
| The Koetting Associates | St Louis | Missouri | 63144 | United States |
| Optometric Physicians of Middle Tennessee | Nashville | Tennessee | 37205 | United States |
| Speciality Eyecare Group | Kirkland | Washington | 98034 | United States |
| years |
|
| Sex/Gender, Customized | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
|
| Primary | Percentage of Subjects Who Achieve Monocular Uncorrected Distance Visual Acuity (UDVA) of 20/40 or Better in Both Eyes | Using the high contrast distance UDVA collected at the 3-Month Follow-up Visit, subjects with non-missing Snellen VA of 20/40 or less in both eyes will be classified as "20/40 or Better". Subjects with at least one missing value at the 3-Month Follow-up Visit will not be classified and their classification value will be assigned as a missing value. The denominator for percentages will be the number of non-missing values | Posted | Count of Participants | Participants | Assessed at 3 month follow up visit |
|
|
|
| Primary | The Rate of Serious Adverse Events at the Eye Level | Posted | Count of Units | Eyes | Assessed from dispensing through 3 months | Eyes | Eyes |
|
|
|
| 0 |
| 76 |
| 0 |
| 76 |
| 6 |
| 76 |
Not provided
Not provided